{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:09:16Z","timestamp":1793329756981,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anaemia is highly prevalent in cancer patients, adversely affects quality of life and impacts survival. The pathogenesis is multifactorial, with iron deficiency being a major and potentially treatable contributor. This study aimed to assess the effectiveness and economic impact of ferric carboxymaltose in chemotherapy-induced anaemia. This prospective cohort study between 2015\u20132016 of chemotherapy-treated patients for solid tumours, grade \u22652 anaemia and iron deficiency evaluated hematopoietic response four weeks after ferric carboxymaltose treatment. Transfusion rate of all cancer patients treated at our ambulatory unit during the two-year study period (2015\u20132016) was compared to a retrospective cohort (2013\u20132014) who received blood transfusion only. Between 2015\u20132016, 99 patients were included and treated with ferric carboxymaltose, the majority of whom (n\u2009=\u200981) had relative iron deficiency. Mean haemoglobin concentrations improved from 9.2 [6.7\u201310.8] g\/dL to 10.6 [7.8\u201314.2] g\/dL four weeks after treatment. A 26% reduction in the transfusion rate was observed from control retrospective to the prospective study group including ferric carboxymaltose treated patients [relative risk 0.74 (95% CI:0.66\u20130.83)]. The cost analysis showed a benefit for the use of ferric carboxymaltose in chemotherapy-induced anaemia. This study shows that ferric carboxymaltose is an effective, cost-saving support treatment, reducing the need for allogeneic transfusions saving blood units which are a limited resource.<\/jats:p>","DOI":"10.1038\/s41598-019-56999-3","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T11:02:45Z","timestamp":1577790165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion"],"prefix":"10.1038","volume":"9","author":[{"given":"Joana","family":"Marinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cust\u00f3dio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Moreira Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Telma","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c2ngela","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-8989","authenticated-orcid":false,"given":"Ana","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela","family":"Amarelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Joaquim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,31]]},"reference":[{"key":"56999_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/CLEP.S89480","volume":"8","author":"H Xu","year":"2016","unstructured":"Xu, H. et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010\u20132013. Clin. Epidemiol 8, 61\u201371, https:\/\/doi.org\/10.2147\/CLEP.S89480 (2016).","journal-title":"Clin. Epidemiol"},{"key":"56999_CR2","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig, H. et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer 40, 2293\u20132306, https:\/\/doi.org\/10.1016\/j.ejca.2004.06.019 (2004).","journal-title":"European Journal of Cancer"},{"key":"56999_CR3","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","volume":"31 Pt 2","author":"Y Wu","year":"2009","unstructured":"Wu, Y., Aravind, S., Ranganathan, G., Martin, A. & Nalysnyk, L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000\u20132007. Clin. Ther. 31 Pt 2, 2416\u20132432, https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.020 (2009).","journal-title":"Clin. Ther."},{"key":"56999_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3324\/haematol.2014.112813","volume":"100","author":"A Maccio","year":"2015","unstructured":"Maccio, A. et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 100, 124\u2013132, https:\/\/doi.org\/10.3324\/haematol.2014.112813 (2015).","journal-title":"Haematologica"},{"key":"56999_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdh235","volume":"15","author":"D Cella","year":"2004","unstructured":"Cella, D. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Annals of Oncology 15, 979\u2013986, https:\/\/doi.org\/10.1093\/annonc\/mdh235 (2004).","journal-title":"Annals of Oncology"},{"key":"56999_CR6","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/annonc\/mdt118","volume":"24","author":"H Ludwig","year":"2013","unstructured":"Ludwig, H., Muldur, E., Endler, G. & Hubl, W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Annals of Oncology 24, 1886\u20131892, https:\/\/doi.org\/10.1093\/annonc\/mdt118 (2013).","journal-title":"Annals of Oncology"},{"key":"56999_CR7","unstructured":"WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System, http:\/\/www.who.int\/vmnis\/indicators\/haemoglobin.pdf (2011)."},{"key":"56999_CR8","unstructured":"National Comprehensive Cancer Network. Hematopoietic Growth Factors (Version 2.2019), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf (2019)."},{"key":"56999_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s12094-013-1155-5","volume":"16","author":"J de Castro","year":"2014","unstructured":"de Castro, J. et al. Iron deficiency in patients with solid tumours: prevalence and management in clinical practice. Clinical and Translational Oncology 16, 823\u2013828, https:\/\/doi.org\/10.1007\/s12094-013-1155-5 (2014).","journal-title":"Clinical and Translational Oncology"},{"key":"56999_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bjhh.2016.05.009","volume":"38","author":"FA Naoum","year":"2016","unstructured":"Naoum, F. A. Iron deficiency in cancer patients. Revista Brasileira de Hematologia e Hemoterapia 38, 325\u2013330, https:\/\/doi.org\/10.1016\/j.bjhh.2016.05.009 (2016).","journal-title":"Revista Brasileira de Hematologia e Hemoterapia"},{"key":"56999_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/joim.12826","volume":"285","author":"A Tran-Duy","year":"2019","unstructured":"Tran-Duy, A. et al. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J. Intern. Med. 285, 205\u2013214, https:\/\/doi.org\/10.1111\/joim.12826 (2019).","journal-title":"J. Intern. Med."},{"key":"56999_CR12","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1021\/mp400403s","volume":"10","author":"GS Smelick","year":"2013","unstructured":"Smelick, G. S. et al. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol. Pharm. 10, 4055\u20134062, https:\/\/doi.org\/10.1021\/mp400403s (2013).","journal-title":"Mol. Pharm."},{"key":"56999_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/ijctm.S187569","volume":"ume 6","author":"E Bryer","year":"2018","unstructured":"Bryer, E. & Henry, D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. International Journal of Clinical Transfusion Medicine ume 6, 21\u201331, https:\/\/doi.org\/10.2147\/ijctm.S187569 (2018).","journal-title":"International Journal of Clinical Transfusion Medicine"},{"key":"56999_CR14","doi-asserted-by":"publisher","first-page":"vii167","DOI":"10.1093\/annonc\/mdq284","volume":"21","author":"M Dicato","year":"2010","unstructured":"Dicato, M., Plawny, L. & Diederich, M. Anemia in cancer. Annals of Oncology 21, vii167\u2013vii172, https:\/\/doi.org\/10.1093\/annonc\/mdq284 (2010).","journal-title":"Annals of Oncology"},{"issue":"7","key":"56999_CR15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00520-017-3672-1","volume":"25","author":"F. Lebrun","year":"2017","unstructured":"Lebrun, F., Klastersky, J., Levacq, D., Wissam, Y. & Paesmans, M. Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies. 1\u20137, https:\/\/doi.org\/10.1007\/s00520-017-3672-1 (2017).","journal-title":"Supportive Care in Cancer"},{"issue":"4","key":"56999_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/ph11040094","volume":"11","author":"Fabiana Busti","year":"2018","unstructured":"Busti, F., Marchi, G., Ugolini, S., Castagna, A. & Girelli, D. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel) 11, https:\/\/doi.org\/10.3390\/ph11040094 (2018).","journal-title":"Pharmaceuticals"},{"key":"56999_CR17","doi-asserted-by":"publisher","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","volume":"29","author":"M Aapro","year":"2018","unstructured":"Aapro, M. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 29, iv96\u2013iv110, https:\/\/doi.org\/10.1093\/annonc\/mdx758 (2018).","journal-title":"Ann. Oncol."},{"key":"56999_CR18","unstructured":"Julia, B. et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO\/ASH Clinical Practice Guideline Update. Journal of Clinical Oncology 0, JCO.18.02142, https:\/\/doi.org\/10.1200\/JCO.18.02142%M30969847%U, https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.18.02142."},{"key":"56999_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1358863X10388346","volume":"16","author":"S Sanon","year":"2011","unstructured":"Sanon, S., Lenihan, D. J. & Mouhayar, E. Peripheral arterial ischemic events in cancer patients. Vasc. Med. 16, 119\u2013130, https:\/\/doi.org\/10.1177\/1358863X10388346 (2011).","journal-title":"Vasc. Med."},{"key":"56999_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.bjc.6605498","volume":"102","author":"J Glaspy","year":"2010","unstructured":"Glaspy, J. et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 102, 301\u2013315, https:\/\/doi.org\/10.1038\/sj.bjc.6605498 (2010).","journal-title":"Br. J. Cancer."},{"key":"56999_CR21","doi-asserted-by":"publisher","first-page":"VIII499","DOI":"10.1093\/annonc\/mdy292","volume":"29","author":"D Henry","year":"2018","unstructured":"Henry, D. et al. Randomized, double-blind, placebo (P)-controlled phase III non- inferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: An ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) <10.0 g\/dL. Annals of Oncology 29, VIII499\u2013VIII500, https:\/\/doi.org\/10.1093\/annonc\/mdy292 (2018).","journal-title":"Annals of Oncology"},{"key":"56999_CR22","doi-asserted-by":"publisher","first-page":"CD003407","DOI":"10.1002\/14651858.CD003407.pub5","volume":"12","author":"T Tonia","year":"2012","unstructured":"Tonia, T. et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. 12, CD003407, https:\/\/doi.org\/10.1002\/14651858.CD003407.pub5 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"56999_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/annonc\/mds338","volume":"24","author":"T Steinmetz","year":"2013","unstructured":"Steinmetz, T. et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann. Oncol. 24, 475\u2013482, https:\/\/doi.org\/10.1093\/annonc\/mds338 (2013).","journal-title":"Ann. Oncol."},{"key":"56999_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00520-015-2728-3","volume":"24","author":"A Toledano","year":"2016","unstructured":"Toledano, A. et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care. Cancer 24, 67\u201375, https:\/\/doi.org\/10.1007\/s00520-015-2728-3 (2016).","journal-title":"Support Care. Cancer"},{"key":"56999_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0302-3","volume":"31","author":"M Hedenus","year":"2014","unstructured":"Hedenus, M. et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol 31, 302, https:\/\/doi.org\/10.1007\/s12032-014-0302-3 (2014).","journal-title":"Med Oncol"},{"issue":"Suppl 1","key":"56999_CR26","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1111\/hdi.12560","volume":"21","author":"M Auerbach","year":"2017","unstructured":"Auerbach, M. & Macdougall, I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int 21(Suppl 1), S83\u2013S92, https:\/\/doi.org\/10.1111\/hdi.12560 (2017).","journal-title":"Hemodial Int"},{"key":"56999_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000496967","volume":"142","author":"GM Rodgers","year":"2019","unstructured":"Rodgers, G. M. & Gilreath, J. A. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy. Acta Haematol 142, 13\u201320, https:\/\/doi.org\/10.1159\/000496967 (2019).","journal-title":"Acta Haematol"},{"key":"56999_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/2040620714521127","volume":"5","author":"DB Bregman","year":"2014","unstructured":"Bregman, D. B. & Goodnough, L. T. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Therapeutic advances in hematology 5, 48\u201360, https:\/\/doi.org\/10.1177\/2040620714521127 (2014).","journal-title":"Therapeutic advances in hematology"},{"key":"56999_CR29","unstructured":"Pharma, V. Ferinject (ferric carboxymaltose). Summary Product Characteristics, https:\/\/www.medicines.org.uk\/emc\/product\/5910 (2018)."},{"key":"56999_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40261-015-0361-z","volume":"36","author":"C Rognoni","year":"2016","unstructured":"Rognoni, C., Venturini, S., Meregaglia, M., Marmifero, M. & Tarricone, R. Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Clin. Drug. Investig. 36, 177\u2013194, https:\/\/doi.org\/10.1007\/s40261-015-0361-z (2016).","journal-title":"Clin. Drug. Investig."},{"key":"56999_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ndt\/gft251","volume":"29","author":"JE Onken","year":"2014","unstructured":"Onken, J. E. et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol. Dial. Transplant 29, 833\u2013842, https:\/\/doi.org\/10.1093\/ndt\/gft251 (2014).","journal-title":"Nephrol. Dial. Transplant"},{"key":"56999_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/trf.12289","volume":"54","author":"JE Onken","year":"2014","unstructured":"Onken, J. E. et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 54, 306\u2013315, https:\/\/doi.org\/10.1111\/trf.12289 (2014).","journal-title":"Transfusion"},{"key":"56999_CR33","doi-asserted-by":"publisher","unstructured":"Wolf, M. et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 3, https:\/\/doi.org\/10.1172\/jci.insight.124486 (2018).","DOI":"10.1172\/jci.insight.124486"},{"key":"56999_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/THC-151074","volume":"24","author":"X Calvet","year":"2016","unstructured":"Calvet, X. et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technology and Health Care 24, 111\u2013120, https:\/\/doi.org\/10.3233\/THC-151074 (2016).","journal-title":"Technology and Health Care"},{"key":"56999_CR35","doi-asserted-by":"publisher","first-page":"e45604","DOI":"10.1371\/journal.pone.0045604","volume":"7","author":"X Calvet","year":"2012","unstructured":"Calvet, X. et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One 7, e45604, https:\/\/doi.org\/10.1371\/journal.pone.0045604 (2012).","journal-title":"PLoS One"},{"key":"56999_CR36","doi-asserted-by":"publisher","first-page":"A843","DOI":"10.1016\/j.jval.2015.09.386","volume":"18","author":"AB Vicente","year":"2015","unstructured":"Vicente, A. B., Decimoni, T. C. & Quero, A. A. Cost-minimization analysis of the carboxymaltose ferric (i.v.) Compared with sacarato ferric (i.v.) in the treatment of anemia under suplementary health care perspective. Value in Health 18, A843, https:\/\/doi.org\/10.1016\/j.jval.2015.09.386 (2015).","journal-title":"Value in Health"},{"key":"56999_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3280\/MESA2015-023006","volume":"93","author":"C Rognoni","year":"2015","unstructured":"Rognoni, C., Tarricone, R. & Meregaglia, M. Impatto economico dell\u2019utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane. MECOSAN. Manag. Econ. Sanit. 93, 99\u2013114, https:\/\/doi.org\/10.3280\/MESA2015-023006 (2015).","journal-title":"MECOSAN. Manag. Econ. Sanit."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56999-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T18:20:38Z","timestamp":1671301238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56999-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,31]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["56999"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56999-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,31]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20410"}}